Shandong Sito Bio-technology Co

Shandong Sito Bio-technology Co Current Liabilities

The Current Liabilities of Shandong Sito Bio-technology Co (300583.SZ) as of Nov 3, 2026 is 292.73 M CNY. In the previous year, Current Liabilities was 1.07 B CNY — a change of -72.70% (lower).

Current Liabilities

292.73 MCNY

YoY

-72.70%

Last updated:

Current Liabilities of Shandong Sito Bio-technology Co is 2025 292.73 M CNY. Current Liabilities of Shandong Sito Bio-technology Co was 2024 1.07 B CNY. It decreases by -72.70% lower compared to the previous year.

The Shandong Sito Bio-technology Co Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
764.21 M CNY
Jan 1, 2019
972.26 M CNY
Jan 1, 2020
975.46 M CNY
Jan 1, 2021
1.02 B CNY
Jan 1, 2022
1.13 B CNY
Jan 1, 2023
1.05 B CNY
Jan 1, 2024
1.07 B CNY
Jan 1, 2025
292.73 M CNY
The Shandong Sito Bio-technology Co Current Liabilities history
YEARCurrent LiabilitiesYoY
292.73 MCNY-72.70%
1.07 BCNY+1.90%
1.05 BCNY-6.55%
1.13 BCNY+9.95%
1.02 BCNY+4.98%
975.46 MCNY+0.33%
972.26 MCNY+27.23%
764.21 MCNY+192.81%
260.99 MCNY+6.71%
244.58 MCNY+11.20%
219.96 MCNY+75.63%
125.24 MCNY+58.89%
78.82 MCNY+188.19%
27.35 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shandong Sito Bio-technology Co Stock analysis

What does Shandong Sito Bio-technology Co do? Shandong Sito Bio-technology Co., Ltd. generates revenue through three product segments. The Steroid Raw Materials segment produces steroid raw materials like androstenedione and 9-hydroxyandrostenedione using genetic engineering and microbial transformation technology. The Steroidal Finished Drug segment and Non-Steroidal Finished Drug segment are operated via its subsidiary, offering finished pharmaceutical products. The company's primary customers are pharmaceutical manufacturers requiring raw materials and finished drugs for further processing. The Steroid Raw Materials segment focuses on manufacturing key compounds such as androstenedione, hydroxyprogesterone, and 9-hydroxyandrostenedione. These materials are essential for the production of various steroid-based pharmaceuticals. The Steroidal Finished Drug segment provides ready-to-use pharmaceutical products, while the Non-Steroidal Finished Drug segment offers non-steroid alternatives, targeting different medical needs. Shandong Sito serves pharmaceutical companies that need raw materials for steroid-based drugs and finished drugs for distribution. The Steroid Raw Materials segment supplies critical inputs for steroid pharmaceutical production, while the Steroidal and Non-Steroidal Finished Drug segments cater to end-market demand for completed pharmaceutical products. The company's operations are centered around biotechnology-driven manufacturing of pharmaceutical ingredients and finished drugs. Shandong Sito Bio-technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shandong Sito Bio-technology Co stock

Current Liabilities of Shandong Sito Bio-technology Co is 292.73 M CNY in 2025.

Current Liabilities of Shandong Sito Bio-technology Co changed from 1.07 B CNY to 292.73 M CNY, representing a -72.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Shandong Sito Bio-technology Co since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Shandong Sito Bio-technology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Shandong Sito Bio-technology Co

All Key Metrics — Shandong Sito Bio-technology Co